Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure-activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Hui Jin Jung, Eun Hye Nam, Jin Young Park, Prithwish Ghosh, In Su Kim. Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor. Bioorganic & medicinal chemistry letters. 2021 Apr 01;37:127846

Mesh Tags

Substances

PMID: 33571650

search → result